Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548955 | 0.90 | OPRM1 (0.59) | OPRL1OPRM1OPRK1MAPTKDM4E | |
| SCHEMBL2490968 | 0.90 | OPRM1 (0.59) | OPRL1OPRM1OPRK1MAPTKDM4E | |
| SCHEMBL13001593 | 0.87 | OPRL1 (0.59) | OPRL1OPRM1OPRK1MAPTKDM4E | |
| SCHEMBL30411919 | 0.86 | OPRL1 (0.60) | OPRL1OPRM1OPRK1MAPTKDM4E | |
| SCHEMBL15579138 | 0.86 | OPRL1 (0.60) | OPRL1OPRM1OPRK1MAPTKDM4E | |
| SCHEMBL16627546 | 0.86 | OPRL1 (0.60) | OPRL1OPRM1OPRK1MAPTKDM4E | |
| SCHEMBL8872036 | 0.85 | OPRL1 (0.47) | OPRL1OPRM1OPRK1CHRM1EGLN1 | |
| SCHEMBL30574150 | 0.85 | OPRL1 (0.63) | OPRL1OPRM1OPRK1MAPTKDM4E | |
| SCHEMBL8320599 | 0.84 | OPRL1 (0.67) | OPRL1OPRM1OPRK1EGLN1OPRD1 | |
| SCHEMBL26021860 | 0.84 | OPRL1 (0.56) | OPRL1OPRM1OPRK1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| US-6013652-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIHISTAMINES | MERCK & CO., INC. (US) | 2000-01-11 | — | — | US | disclosed |
| US-5962462-A | COMPOUNDS WHICH INHIBIT THE ENTRY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTO TARGET CELLS; DELAYING THE ONSET OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). | MERCK & CO., INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1998025605-A1 | SPIRO-SUBSTITUTED AZACYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | OPRL1 2333/4885OPRM1 1519/4885OPRK1 1945/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | OPRL1 2097/4885OPRM1 1433/4885OPRK1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.